30 pharmas including Hanmi Pharm challenge the ‘diabetic neuropathy therapy market’

Since ‘Dexid(generic name: R-thioctic acid tromethamine),’ a diabetic neuropathy therapy, was expired for the PMS(Post-Marketing Surveillance), 30 pharmaceutical companies including Hanmi Pharm and Chong Kun Dang are reportedly getting ready to launch its generic.

‘Dixid’ is an incrementally modified medicine Bukwang Pharm developed to protect its generic market after the original product ‘Thi...